JLE

Journal de Pharmacie Clinique

MENU

Search of an ifosfamide encephalopathy treatment protocol by methylene blue Volume 18, issue 1, Mars 1999

Figures

See all figures

Authors

In cancer chemotherapy with ifosfamide, the occurrence of a drug-related encephalopathy represents a severe adverse effect of unknown origine. The underlying mechanism probably residing in the mitochondrial toxicity suggests the use of the electron accepting drug methylene blue to inhibit the signs of this neurotoxicity. The clinical cases of ifosfamide encephalopathy treated by methylene blue, collected in the litterature and in the oncology service of the hôpitaux universitaires de Strasbourg, allowed the elaboration of a neurotoxicity treatment protocol. This protocol has to be validated by cancerology experts, and let envisage a clinical trial realisation.